Dietel M, Bodecker R, Arps H, Bahnsen J, Hölzel F
Geburtshilfe Frauenheilkd. 1985 Apr;45(4):213-9. doi: 10.1055/s-2008-1037348.
Epithelial tumours of the ovary with a tumour status between benign and malignant are classified as borderline tumours (BOT). They are particularly frequent in women between 30 and 40 years of age, emphasising the need for effecting a therapy directed at preserving fertility. To keep the risk of this therapy at a minimum it is imperative to effect accurate determination of the prognosis on the basis of an examination of the histological preparation. Conventional histology is insufficient for this purpose, thus requiring the use of additional morphological methods. In the present study the DNA of the cell nucleus was determined via quantitative cytophotometry and also via several tumour or differentiating markers by immunohistology, in healthy ovaries, 10 benign and 20 malignant ovarian tumours and in 20 borderline tumours (BOT). The DNA histograms of the tumours classified histologically as BOT, yielded distribution patterns pointing towards a benign, proliferative or malignant potency of the tumours without a correlation to conventional histology being present in each case. Immunohistological identification of the carcinoembryonal antigen (CEA) and of the blood group substances (A, B, Lewis, Lewis) produced characteristic distribution patterns which correlated with the tendency to proliferation in DNA cytophotometry. To achieve relevant determination of prognosis of BOT in individual cases, conventional histology should be complemented by additional examinations using DNA cytophotometry and immunhistology as diagnostic tools.
肿瘤状态介于良性和恶性之间的卵巢上皮性肿瘤被归类为交界性肿瘤(BOT)。它们在30至40岁的女性中尤为常见,这凸显了实施旨在保留生育能力的治疗的必要性。为了将这种治疗的风险降至最低,必须在对组织学切片进行检查的基础上准确确定预后。传统组织学不足以达到这一目的,因此需要使用额外的形态学方法。在本研究中,通过定量细胞光度法以及免疫组织化学方法利用几种肿瘤或分化标志物,对健康卵巢、10例良性卵巢肿瘤、20例恶性卵巢肿瘤以及20例交界性肿瘤(BOT)的细胞核DNA进行了测定。组织学上归类为BOT的肿瘤的DNA直方图产生的分布模式表明肿瘤具有良性、增殖性或恶性潜能,且每种情况均与传统组织学无相关性。癌胚抗原(CEA)和血型物质(A、B、Lewis、Lewis)的免疫组织化学鉴定产生了与DNA细胞光度法中的增殖趋势相关的特征性分布模式。为了在个体病例中对BOT的预后进行相关测定,传统组织学应以使用DNA细胞光度法和免疫组织化学作为诊断工具的额外检查作为补充。